314 related articles for article (PubMed ID: 35609554)
1. Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab.
Veleiro-Pérez B; Alba-Muñoz J; Pérez-Quintero O; Rodríguez RL; Calvín-Lamas M; Parra-Arrondo A
Int Arch Allergy Immunol; 2022; 183(10):1089-1094. PubMed ID: 35609554
[TBL] [Abstract][Full Text] [Related]
2. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics, Investigations and Treatment in Children with Chronic Urticaria: An Observational Study.
Buono EV; Giannì G; Scavone S; Caffarelli C
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792886
[No Abstract] [Full Text] [Related]
4. Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.
Kasperska-Zajac A; Jarząb J; Żerdzińska A; Bąk K; Grzanka A
Int J Immunopathol Pharmacol; 2016 Jun; 29(2):320-8. PubMed ID: 26729404
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
Cakmak ME
Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
[TBL] [Abstract][Full Text] [Related]
6. Delayed Pressure Urticaria: A Systematic Review of Treatment Options.
Kulthanan K; Ungprasert P; Tuchinda P; Chularojanamontri L; Charoenpipatsin N; Maurer M
J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2035-2049.e5. PubMed ID: 32179196
[TBL] [Abstract][Full Text] [Related]
7. Chronic Urticaria: An Overview of Treatment and Recent Patents.
Hon KL; Leung AKC; Ng WGG; Loo SK
Recent Pat Inflamm Allergy Drug Discov; 2019; 13(1):27-37. PubMed ID: 30924425
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
9. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
[TBL] [Abstract][Full Text] [Related]
10. UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities.
Staubach P; Bilo B; Fluhr JW; Krause K; Kulthanan K; Salman A; Katelaris C; Bernstein JA; Maurer M; Mann C
J Dermatolog Treat; 2024 Dec; 35(1):2329784. PubMed ID: 38508226
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
12. Long-term management of chronic spontaneous urticaria with omalizumab.
Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
Gimenez-Arnau AM; Salman A; Podder I
Eur J Dermatol; 2024 Feb; 34(1):3-12. PubMed ID: 38557452
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
[TBL] [Abstract][Full Text] [Related]
17. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
Salman A; Ergun T; Gimenez-Arnau AM
J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
[No Abstract] [Full Text] [Related]
18. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of as-needed antihistamines in chronic spontaneous urticaria patients under omalizumab treatment.
Türk M; Yılmaz İ; Nazik Bahçecioğlu S; Can P; Ertaş R; Kartal D; Çınar SL; Kocatürk E
Dermatol Ther; 2021 Jan; 34(1):e14543. PubMed ID: 33190334
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Omalizumab in Elderly Patients with Chronic Urticaria: Is It a Safe Therapy?
Narváez-Fernández EJ; Entrala A; Nin-Valencia A; Mir-Ihara P; Losantos-García I; Domínguez-Ortega J; González-Fernández MÁ; Quirce S; Hernández-Cano N; Cabañas R; Caballero T
Int Arch Allergy Immunol; 2023; 184(10):1003-1009. PubMed ID: 37231812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]